gsk-2816126 and Lupus-Nephritis

gsk-2816126 has been researched along with Lupus-Nephritis* in 1 studies

Other Studies

1 other study(ies) available for gsk-2816126 and Lupus-Nephritis

Article	Year
EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice. Frontiers in immunology, 2021, Volume: 12 Topics: Animals; Cell Line; Disease Models, Animal; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Humans; Indoles; Interferon Type I; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Mice, Inbred NZB; Mice, Transgenic; Pyridones; Signal Transduction; Treatment Outcome	2021

Article

Year

EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice.

Frontiers in immunology, 2021, Volume: 12

Topics: Animals; Cell Line; Disease Models, Animal; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Humans; Indoles; Interferon Type I; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Mice, Inbred NZB; Mice, Transgenic; Pyridones; Signal Transduction; Treatment Outcome

2021